Literature DB >> 33596985

Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages.

Jingyi Zhou1, Weiyu Wang1, Qi Li2.   

Abstract

In hepatocellular carcinoma patients, due to the microenvironmental specificity of liver, the tumor microenvironment exhibits high immunosuppression and drug resistance, resulting in excessive or insufficient responses to immunotherapy. The dynamic interactions between tumor cells and immune modulators in the TME significantly impact the occurrence and development of tumors, efficacy, and drug resistance, which can create a much more positive response to immunotherapy. Moreover, with the wide application of single-cell sequencing technology in the TME, increasing evidence shows an interaction network among cells. Sequencing results suggest that specific tumor-associated macrophages are a hub node, connecting different cell populations in the cell interaction network, and can could regulate tumor generation and antitumor immunity. This review focused on therapeutic targets that could be targeted to remodel the tumor microenvironment and reprogram the tumor-associated macrophage phenotype in hepatocellular carcinoma patients, thereby improving immunotherapeutic efficacy.

Entities:  

Keywords:  Antitumor immunity; Hepatocellular carcinoma; Immune checkpoint; Immunotherapy; Tumor microenvironment; Tumor-associated macrophages

Year:  2021        PMID: 33596985     DOI: 10.1186/s13046-021-01873-2

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  83 in total

1.  Nutrition classics from the: Biochemical Journal 20: 497-501, 1926. LXIV. Colour reactions attributed to vitamin A. By Francis Howard Carr and Ernest Arthur Price.

Authors: 
Journal:  Nutr Rev       Date:  1973-10       Impact factor: 7.110

2.  The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease.

Authors:  H Rao; E Wu; S Fu; M Yang; B Feng; A Lin; R Fei; R J Fontana; A S Lok; L Wei
Journal:  Aliment Pharmacol Ther       Date:  2017-08-22       Impact factor: 8.171

3.  Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes.

Authors:  Sunyoung Lee; Tae Wook Kang; Dong Ik Cha; Kyoung Doo Song; Min Woo Lee; Hyunchul Rhim; Hyo Keun Lim; Dong Hyun Sinn; Jong Man Kim; Kyunga Kim
Journal:  J Hepatol       Date:  2018-03-08       Impact factor: 25.083

Review 4.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

5.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 6.  Turning Cold into Hot: Firing up the Tumor Microenvironment.

Authors:  Qianqian Duan; Hualing Zhang; Junnian Zheng; Lianjun Zhang
Journal:  Trends Cancer       Date:  2020-03-21

Review 7.  Goals and targets for personalized therapy for HCC.

Authors:  Thomas Couri; Anjana Pillai
Journal:  Hepatol Int       Date:  2019-01-01       Impact factor: 6.047

Review 8.  Pathogenesis of liver cirrhosis.

Authors:  Wen-Ce Zhou; Quan-Bao Zhang; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

9.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

Review 10.  A global view of hepatocellular carcinoma: trends, risk, prevention and management.

Authors:  Ju Dong Yang; Pierre Hainaut; Gregory J Gores; Amina Amadou; Amelie Plymoth; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08-22       Impact factor: 73.082

View more
  5 in total

1.  Development and validation of genomic and epigenomic signatures associated with tumor immune microenvironment in hepatoblastoma.

Authors:  Yanbing Zhang; Tian Zhang; Qiang Yin; Haiyan Luo
Journal:  BMC Cancer       Date:  2021-10-29       Impact factor: 4.430

Review 2.  Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.

Authors:  Rui Xing; Jinping Gao; Qi Cui; Qian Wang
Journal:  Front Immunol       Date:  2021-11-26       Impact factor: 7.561

Review 3.  Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options.

Authors:  Zuzanna Sas; Ewa Cendrowicz; Isabel Weinhäuser; Tomasz P Rygiel
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

Review 4.  Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology.

Authors:  Sandra Mirie Kang; Lana Khalil; Bassel F El-Rayes; Mehmet Akce
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

5.  Characterization of somatic mutations and pathway alterations during hepatocellular carcinoma vascular invasion using next-generation sequencing.

Authors:  Qi Li; Qifan Zhang; Jinzhang Chen; Mengya Zang; Xiaoyun Hu; Rong Li; Jinlin Hou; Jie Zhou
Journal:  J Gastrointest Oncol       Date:  2022-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.